GSK reports Nucala approved by FDA for adults with COPD

GSK (GSK) announced that the U.S. Food and Drug Administration has approved Nucala as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK, said: “The approval of Nucala in the US provides an important option for COPD patients. Long-term follow-up studies have demonstrated that exacerbations are the single most important predictor of future risk, with particularly poor outcomes in those requiring hospital visits or admissions. Today there is hope for improved care for COPD patients with an eosinophilic phenotype, including those with a BEC threshold as low as greater than or equal to 150cells/muL who need new options like Nucala to support their treatment journey.”